NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been given an average rating of "Moderate Buy" by the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $15.50.

Several equities analysts have issued reports on NPCE shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $17.00 price objective on shares of NeuroPace in a research report on Wednesday, May 14th. JPMorgan Chase & Co. lifted their target price on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright began coverage on NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 target price for the company.

NeuroPace Price Performance

Shares of NeuroPace stock traded down $0.19 during midday trading on Friday, hitting $10.41. 273,019 shares of the company were exchanged, compared to its average volume of 171,958. The company has a debt-to-equity ratio of 2.46, a current ratio of 6.63 and a quick ratio of 5.70. The firm has a market cap of $341.45 million, a P/E ratio of -12.39 and a beta of 2.03. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.98. The firm has a 50 day simple moving average of $12.83 and a 200-day simple moving average of $12.39.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. The business had revenue of $22.52 million during the quarter, compared to the consensus estimate of $21.85 million. NeuroPace had a negative return on equity of 190.84% and a negative net margin of 29.42%. Research analysts forecast that NeuroPace will post -1 earnings per share for the current year.

Insider Buying and Selling at NeuroPace

In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the sale, the insider now directly owns 3,238,199 shares in the company, valued at $51,325,454.15. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 20.50% of the company's stock.

Institutional Trading of NeuroPace

A number of institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its holdings in shares of NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock valued at $212,000 after purchasing an additional 2,267 shares in the last quarter. Petrus Trust Company LTA bought a new stake in shares of NeuroPace in the first quarter valued at about $165,000. First Light Asset Management LLC bought a new stake in shares of NeuroPace in the first quarter valued at about $19,468,000. Birchview Capital LP lifted its holdings in shares of NeuroPace by 64.4% in the first quarter. Birchview Capital LP now owns 16,442 shares of the company's stock valued at $202,000 after purchasing an additional 6,442 shares in the last quarter. Finally, Ghisallo Capital Management LLC bought a new stake in shares of NeuroPace in the first quarter valued at about $2,458,000. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.